Mercados españoles cerrados

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
42,27-0,11 (-0,26%)
Al cierre: 04:00PM EDT
42,31 +0,04 (+0,09%)
Después del cierre: 06:38PM EDT

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048
https://www.cerevel.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo334

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. N. Anthony Coles Jr., M.P.H.Executive Chairman1,14MN/A1960
Mr. Mark BodenraderVP of Finance & Chief Accounting Officer496,17kN/A1973
Dr. John J. Renger Ph.D.Chief Scientific Officer779,75k10,44M1969
Dr. Ramiro Sanchez M.D.Chief Medical Officer805,13kN/A1961
Mr. Ronald C. Renaud Jr., M.B.A.President, CEO & DirectorN/AN/A1969
Dr. Susan Altschuller M.B.A., Ph.D.Chief Financial OfficerN/AN/A1982
Mr. Matthew CalistriVice President of Investor RelationsN/AN/AN/A
Mr. Scott M. Akamine J.D.Chief Legal Officer & Corporate Secretary444,74kN/A1985
Mr. Kenneth A. DiPietroChief Human Resources OfficerN/AN/A1959
Ms. Kathleen Tregoning M.A.Chief Corporate Affairs Officer600,79kN/A1971
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Cerevel Therapeutics Holdings, Inc., a día 1 de marzo de 2024, es 6. Las puntuaciones base son Auditoría: 8; Tablero: 7; Derechos de los accionistas: 5; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.